A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

We recently compiled a list of the 13 Highest Yielding Dividend Stocks in the Dow. In this article, we are going to take a ...

In the CodeBreaK 300 trial, sotorasib and panitumumab had better response rates and improved PFS vs standard-of-care ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Ribometrix, a spinout of UNC-Chapel Hill, has named William Marshall as its new CEO, succeeding former chief executive ...

Arcus Biosciences named former Amgen executive Richard Markus as its chief medical officer. The biopharmaceutical company, which is focused on cancer treatments, said Tuesday that Markus is scheduled ...

Wells Fargo sees downside to Amgen’s (AMGN) 2025 consensus estimates, saying the company’ sales guidance could came in below expectations. It ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $272.11 which represents a slight increase of $2.68 or 0.99% from the prior close of $269.43. The stock opened at $276.97 and touched a ...

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.